Regenerex Pharma (RGPX) Notes Payables (2010 - 2025)

Regenerex Pharma (RGPX) has 12 years of Notes Payables data on file, last reported at $2.8 million in Q3 2025.

• Notes Payables for Q3 2025 came in at $2.8 million, up 20759.49% year-over-year; the trailing twelve-month figure through Sep 2025 was $2.8 million (up 20759.49% YoY), and the FY2025 annual result was $2.8 million, up 2271.03% from the prior year.
• Notes Payables was little changed at $2.8 million in Q3 2025 per RGPX's latest filing, from $2.8 million in the prior quarter.
• Over five years, Notes Payables peaked at $2.8 million in Q3 2025 and troughed at $1600.0 in Q2 2024.
• A 5-year average of $993790.9 and a median of $314704.0 in 2023 frame the typical range for Notes Payables.
• The sharpest annual moves came in 2024 and 2025: Notes Payables tumbled 99.43% in 2024, then surged 177595.75% in 2025.
• A 5-year view of Notes Payables shows it stood at $349754.0 in 2021, then dropped by 3.54% to $337369.0 in 2022, then jumped by 611.39% to $2.4 million in 2023, then climbed by 17.68% to $2.8 million in 2024, then gained by 0.83% to $2.8 million in 2025.
• Business Quant data shows RGPX's Notes Payables at $2.8 million in Q3 2025, $2.8 million in Q2 2025, and $2.8 million in Q1 2025.